Accession Number:

ADA455234

Title:

Broad Spectrum Chemotherapy: A Novel Approach Using Beta-Galactosidase Activated Pro-Drugs

Descriptive Note:

Annual summary rept. 1 Mar 2005-28 Feb 2006

Corporate Author:

TEXAS UNIV AT DALLAS SOUTHWESTERN MEDICAL CENTER

Personal Author(s):

• Liu, Li

Report Date:

2006-03-01

Pagination or Media Count:

17.0

Abstract:

Gene therapy shows promise for treating prostate cancer and is being exploited in several clinical trials. A major hurdle is establishing a method of verifying transgene activity in situ. beta-galactosidase beta-gal was historically the most popular reporter gene for molecular biology. I have introduced a novel concept for further exploration of gene therapy using beta-galactosidase to activate a broad-spectrum chemotherapeutic to assess the efficacy of the pro-drugs in vitro and explore growth delay in animal models. I also have developed a new beta-galactosidase molecular reporter for MRI spectra, which can be used to detection of lacZ gene expression in vivo.

Descriptors:

• *DRUGS
• *CHEMOTHERAPY
• *GROWTH(PHYSIOLOGY)
• *GENE THERAPY
• *PROSTATE CANCER
• DETECTION
• DELAY
• CLINICAL TRIALS
• MOLECULAR BIOLOGY
• IN VIVO ANALYSIS
• GENES
• ANIMALS

Subject Categories:

• Biochemistry
• Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE